三度登顶！药明生物再获EcoVadis最高“铂金”评级，稳居全球前1%

上海,

2026年2月9日

药明生物（WuXi Biologics, 2269.HK）宣布，公司获得国际权威企业可持续发展评估机构EcoVadis授予的最高殊荣“铂金”评级。药明生物凭借在可持续发展领域的杰出成绩，连续三年获此认可。

EcoVadis是国际权威企业可持续发展评估机构之一，其评级从环境、劳工与人权、商业道德和可持续采购四大主题进行评估，下设21项可持续发展标准，全面衡量企业的可持续发展表现。

药明生物从全球逾15万家参评企业中脱颖而出，位列前1%，凭借完善的ESG政策体系、严格的执行机制及经实践验证的成效，获得外部利益相关方及第三方专业机构的高度认可。

药明生物持续在EcoVadis的各项评估领域中精进可持续发展表现。近期举措包括：

温室气体减排目标获SBTi认证：

药明生物近期及净零温室气体减排目标已获科学碳目标倡议（Science Based Targets initiative，SBTi）认证，成为行业内首批获SBTi近期及净零减排目标认证的企业之一。

发布《药明生物Green CRDMO白皮书》：

《药明生物Green CRDMO白皮书》在推动生物药行业可持续发展进程的同时，详尽展现药明生物在生物药研究、开发和生产环节的绿色创新技术及公司绿色可持续运营的节能减碳成果。此《白皮书》共汇聚242个优秀节能案例，覆盖生物制药行业12大能源系统及5大关键节能场景，运用25类节能技术。

成功通过ISO 20400认证：

公司通过了ISO 20400可持续采购体系认证，这一国际标准是全球公认的可持续采购指南，旨在帮助企业将可持续发展原则融入采购流程，推动构建负责任、透明的供应链。

连续三年获得 EcoVadis 铂金评级，进一步巩固了全球客户对药明生物作为可靠、负责、且具有前瞻性合作伙伴的信心，彰显了公司在不断演进的全球ESG环境中，始终以严谨的可持续发展、质量与合规要求为原则，支持长期合作的稳健推进。

作为联合国全球契约组织（UNGC）成员和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得明晟（MSCI）最高AAA ESG评级、入选道琼斯可持续发展指数（DJSI）；荣登CDP气候变化、水安全和供应商参与度三大领域A级榜单；获评晨星Sustainalytics ESG“风险可忽略”最高评级以及“行业最高评级”与“区域最高评级”企业；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。

关于药明生物

WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally

Shanghai,

February 9, 2026

WuXi Biologics (2269.HK), announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received the rating's highest level of recognition.

EcoVadis is among the world's most trusted and comprehensive sustainability assessment platforms, evaluating companies' ESG performance through 21 criteria across four key areas — Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. 

WuXi Biologics was ranked in the top 1% of more than 150,000 companies evaluated worldwide. Being awarded the Platinum Medal reflects company's robust policies, rigorous implementation mechanisms, and proven performance outcomes across all ESG dimensions, validated by external stakeholders and third-party professionals.

WuXi Biologics continues to strengthen its sustainability performance across the EcoVadis assessment areas. Examples of recent initiatives include:

SBTi-Approved Targets: The company's near-term and net-zero GHG emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), making WuXi Biologics one of the first in the industry to receive approval for both near-term and net-zero targets.

Green CRDMO White Paper: The White Paper — launched to accelerate sustainability in the biologics industry — details WuXi Biologics' green innovation technologies across research, development and manufacturing, and showcases the significant carbon reduction achieved through green operations. It also compiles 242 energy-saving cases across five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories.

ISO 20400 Certification: The company has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles and procurement practices, while promoting transparency and responsibility across the supply chain.

Dr. Chris Chen

Chief Executive Officer

Chairman of the ESG Committee

WuXi Biologics

Achieving the EcoVadis Platinum Medal for the third consecutive year, WuXi Biologics further reinforces global clients' confidence in its reliability, responsibility, and forward-thinking vision, with unwavering adherence to rigorous sustainability, quality, and compliance standards for long-term collaborations in the evolving global ESG landscape.

As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for both Climate Change and Water Security, and rated "A" in the CDP Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.